SPPI New Lead Plaintiff Deadline: Contact Robbins LLP for Information About Leading the Class Action Against SPPI

Group 1 - The core issue involves a class action lawsuit against Spectrum Pharmaceuticals, alleging false or misleading statements regarding its Pinnacle Study related to the drug poziotinib for lung cancer treatment [2] - The Lead Plaintiff appointment process for the class action has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [1][3] - Spectrum Pharmaceuticals focuses on acquiring, developing, and commercializing novel and targeted oncology therapies [1] Group 2 - The lawsuit claims that the company misrepresented information that could affect investor decisions, particularly concerning the clinical trial results of poziotinib [2] - Robbins LLP, the law firm involved, emphasizes that shareholders do not need to participate in the case to be eligible for recovery [3] - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]